Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Multiple of the Median

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: Multiple of the Median. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-002810-15 Sponsor Protocol Number: CHUB-Neuro-ENMG-MS Start Date*: 2021-06-25
    Sponsor Name:CHU Brugmann
    Full Title: Peripheral neuropathy as potential side effect in patients with multiple sclerosis treated with teriflunomide.
    Medical condition: Multiple sclerosis, treated with teriflunomide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003145-99 Sponsor Protocol Number: CCMROne Start Date*: 2015-03-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis alread...
    Medical condition: Relapsing-remitting multiple sclerosis already on interferon-beta therapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005139-14 Sponsor Protocol Number: 54767414SMM2001 Start Date*: 2015-05-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma
    Medical condition: Smoldering multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) CZ (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006751-48 Sponsor Protocol Number: 08/0170 Start Date*: 2009-08-12
    Sponsor Name:University College London [...]
    1. University College London
    2. CR UK and UCL Cancer Trials Centre
    Full Title: PHASE II STUDY OF BORTEZOMIB CONSOLIDATION AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005847-29 Sponsor Protocol Number: MM-VPD-2011 Start Date*: 2012-02-15
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose Therapy
    Medical condition: Multiple Myeloma patients candidate to high-dose therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002740-41 Sponsor Protocol Number: POMDEFIL Start Date*: 2015-02-26
    Sponsor Name:Fundación Pethema
    Full Title: Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in combination with Pomalidomide and Dexamethasone for relapsed/refractory MM patients
    Medical condition: Patients with Multiple Myeloma in relapsed or refractory
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015766-56 Sponsor Protocol Number: FER-AOC-MM Start Date*: 2009-12-02
    Sponsor Name:Vifor Pharma Inc.
    Full Title: A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and ir...
    Medical condition: Treatment of anaemic subjects with multiple myeloma and iron restricted erythropoiesis receiving chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028228 Multiple myeloma LLT
    12.0 10049467 Erythropoiesis abnormal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010875-26 Sponsor Protocol Number: CBHQ880A2203 Start Date*: 2011-08-11
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio clínico en Fase 2, doble ciego, controlado con placebo y aleatorizado de BHQ880, anticuerpo monoclonal (AcM) anti-Dickkopf1 (DKK1), en pacientes con mieloma múltiple no tratado e insuficie...
    Medical condition: Pacientes con mieloma múltiple no tratado e insuficiencia renal que no hayan recibido tratameinto anterior antimieloma ni tratamiento con bifosfonatos.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10005329 - Blood and lymphatic system disorders 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004937-16 Sponsor Protocol Number: THA PH INT 2005 CL 001 Start Date*: 2006-02-17
    Sponsor Name:Celgene International Sarl
    Full Title: Randomised, Controlled, Open-Label, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma
    Medical condition: Multiple myeloma (MM) is a malignant, lymphoproliferative disease of the B-cell system. The incidence is approximately 4 per 100,000 and it is age-dependent, with an increase in incidence of approx...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed) SK (Completed) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003023-38 Sponsor Protocol Number: GERMAIN Start Date*: 2013-10-30
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Phase II study of Bortezomib, Melphalan, Prednisone (VMP) followed by Lenalidomide maintenance vs. VMP without maintenance in Myeloma patients not eligible to high-dose chemotherapy and autologous ...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005804-16 Sponsor Protocol Number: 1256803 Start Date*: 2013-05-24
    Sponsor Name:CHU de Toulouse
    Full Title: Front-line therapy with Carfilzomib, Lenalidomide, and Dexamethasone (CRd) induction followed by autologous stem cell transplantation, CRd consolidation and Lenalidomide maintenance in Newly Diagn...
    Medical condition: Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006792-42 Sponsor Protocol Number: EAE120 Start Date*: 2022-03-09
    Sponsor Name:Hellenic Society of Hematology (EAE)
    Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Daratumumab, Lenalidomide and Dexamethasone ...
    Medical condition: newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002326-21 Sponsor Protocol Number: GEM-SELIBORDARA Start Date*: 2018-05-11
    Sponsor Name:Fundación PETHEMA
    Full Title: An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and ...
    Medical condition: Patients with refractory or relapsed and refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004151-16 Sponsor Protocol Number: 209628 Start Date*: 2021-11-22
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participa...
    Medical condition: Multiple myeloma = cancer of blood cells in the bone marrow
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003682-14 Sponsor Protocol Number: Rostock-Recovery 2006 Start Date*: 2007-06-04
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation/Hämatologie und Onkologie mbH
    Full Title: Randomised phase II study on the treatment with pegfilgrastim after autologous blood stem cell transplantation
    Medical condition: Patients suffering from a hematological malignancy (leukemia, lymphoma or multiple myeloma), after autologous blood stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024329 Leukemia LLT
    9.1 10025310 Lymphoma LLT
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002380-42 Sponsor Protocol Number: CRdvsR Start Date*: 2016-10-31
    Sponsor Name:Polish Myeloma Consortium
    Full Title: Phase 3 Randomized trial of carfilzomib, lenalidomide, dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002480-98 Sponsor Protocol Number: MT-3995-E06 Start Date*: 2012-10-26
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral...
    Medical condition: Type II Diabetes Mellitus with Nephropathy and Albuminuria
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-000381-20 Sponsor Protocol Number: 27820 Start Date*: 2007-11-16
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-005995-14 Sponsor Protocol Number: 3133K1-3001-WW(B2521002) Start Date*: 2009-05-29
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea...
    Medical condition: Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005994-79 Sponsor Protocol Number: 3133K1-3000-WW Start Date*: 2008-05-13
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co...
    Medical condition: Enfermedad de Alzheimer Alzheimer Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:06:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA